hyperpolarized-13c-metabolic-magnetic-resonance-spectroscopy

Hyperpolarized <sup>13</sup>C Metabolic Magnetic Resonance Spectroscopy and Imaging

In the past decades, new methods for tumor staging, restaging, treatment response monitoring, and recurrence detection of a variety of cancers have ...

Technische Universität München

This is the first in vivo determination of the vesicular monoamine transporter (VMAT2) density (B(max)) and ligand-transporter affinity (K(d)(app)) in six unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats using micro-positron emission tomography (PET) imaging with [(11)C]-(+)-alpha-dihydrotetrabenazine (DTBZ). A multiple ligand concentration transporter assay (MLCTA) was used to determine a B(max) value of 178+/-32 pmol/mL and a K(d)(app) of 47.7+/-9.3 pmol/mL for the non-lesioned side and 30.52+/-5.84 and 43.4+/-15.52 pmol/mL for the lesioned side, respectively. While B(max) was significantly different between the two sides, no significant difference was observed for the K(d)(app). In addition to demonstrating the feasibility of in vivo Scatchard analysis in rats, these data confirm the expectation that a 6-OHDA lesion does not affect the affinity; a much simpler binding potential (BP) measure can thus be used as a marker of lesion severity (LS) in this rat model of Parkinson's disease. A transporter occupancy curve demonstrated negligible transporter occupancy ( approximately 1%) at a specific activity (SA) of 1100 nCi/pmol (assuming an injected dose of 100 microCi/100 g), while 10% occupancy was estimated at 100 nCi/pmol. An indirect measurement indicated that the degree of occupancy as a function of SA is independent of LS. Finally, BP measurement reproducibility was assessed and found to be 11%+/-7% for the healthy and 8%+/-12% for the lesioned side. Quantitative PET results can thus be obtained even for severely lesioned animals with the striatum on one side not clearly visible provided accurate image analysis methods are used.

In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD.

Studies showed that the dopamine (DA) transporter (DAT) modulates changes in levodopa-derived synaptic dopamine levels (Delta(DA)) in Parkinson's disease (PD). Here we evaluate the relationship between DAT and Delta(DA) in the 6-hydroxydopamine model of Parkinson's disease to investigate these mechanisms as a function of dopaminergic denervation and in relation to other denervation-induced regulatory changes. 27 rats with a unilateral 6-hydroxydopamine lesion (denervation approximately 20-97%) were imaged with (11)C-dihydrotetrabenazine (VMAT2 marker), (11)C-methylphenidate (DAT marker) and (11)C-raclopride (D2-type receptor marker). For denervation <75%Delta(DA) was significantly correlated with a combination of relatively preserved terminal density and lower DAT. For denervation <90%, Delta(DA) was significantly negatively correlated with DAT with a weaker dependence on VMAT2. For the entire data set, no dependence on pre-synaptic markers was observed; Delta(DA) was significantly positively correlated with (11)C-raclopride binding-derived estimates of DA loss. These findings parallel observations in humans, and show that (i) regulatory changes attempt to normalize synaptic DA levels (ii) a lesion-induced functional dependence of Delta(DA) on DAT occurs up to approximately 90% denervation (iii) for denervation < 75% relative lower DAT levels may relate to effective compensation; for higher denervation, lower DAT levels likely contribute to oscillations in synaptic DA associated with dyskinesias.

Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study.

Small animal positron emission tomography (PET) imaging allows in vivo quantification of lesion- or treatment-induced neurochemical changes in animal models of disease. Important for quantification are the kinetic modeling methods used to determine biologically-relevant parameters of tracer-tissue interaction. In this work, we evaluate modeling algorithms for the dopaminergic tracers (11)C-dihydrotetrabenazine (DTBZ), (11)C-methylphenidate (MP), and (11)C-raclopride (RAC), used to image the dopaminergic system in the unilateral 6-hydroxydopamine lesioned rat model of Parkinson's disease. For the presynaptic tracers, PET measures are compared with autoradiographic binding measurements using DTBZ and [(3)H]WIN 35,428 (WIN). We independently developed a new variant of the tissue-input Logan graphical modeling method, and compared its performance with the simplified Logan graphical method and the simplified reference tissue with basis functions method (SRTM), for region of interest (ROI) averaged time activity curves (TACs) and parametric imaging. The modified graphical method was found to be effectively unbiased by target tissue noise and has advantages for parametric imaging, while all tested methods were equivalent for ROI-averaged data.

Positron emission tomography kinetic modeling algorithms for small animal dopaminergic system imaging.

Manganese(II) is employed as a contrast agent with magnetic resonance imaging (MRI) for study of neuronal activation in rats and mice. However, at the concentrations required for MRI, Mn may induce pharmacological or toxic effects. Positron emission tomography (PET) imaging of (52)MnCl2 at tracer doses has the potential to allow similar Mn studies as manganese-enhanced MRI while providing quantitative results and avoiding toxic effects. In this work, (52)MnCl2 is produced and characterized as a PET tracer in phantoms and in rats.

Geoffrey Topping

Department of Nuclear Medicine,
Klinikum rechts der Isar,
Department of Nuclear Medicine, Klinikum rechts der Isar

Technische Universität München

Hyperpolarized ¹³C Metabolic Magnetic Resonance Spectroscopy and Imaging

Geoffrey Topping

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Nuclear Medicine,Klinikum rechts der Isar,Department of Nuclear Medicine, Klinikum rechts der Isar

Technische Universität München

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Department of Nuclear Medicine,
Klinikum rechts der Isar,
Department of Nuclear Medicine, Klinikum rechts der Isar

Hyperpolarized ¹³C Metabolic Magnetic Resonance Spectroscopy and Imaging